Park Ji-Hyun, Lee Yong-Kwang, Lee Chong-Kil, Lee Hee-Sung, Kim Jeong-Hwan, Lee Min-Hyeok, Seo Yu-Jin, Cho Hwangeui, Park Chan-Su
Department of Pharmaceutics, College of Pharmacy, Chungbuk National University, 1 Chungdae-ro, Seowon-gu, Cheongju 28644, Korea.
Sturgeon Bio Co. Ltd, Cheongju 28581, Republic of Korea.
Food Funct. 2025 Jul 1;16(13):5421-5434. doi: 10.1039/d5fo01038a.
Ulcerative colitis (UC), an inflammatory bowel disease, causes inflammation in the colonic mucosa. The pathogenesis of UC is closely linked to abnormalities in the gastrointestinal microbiota and immune response. Current treatments for UC primarily alleviate symptoms but are associated with several drawbacks, particularly with prolonged use. Therefore, there is a crucial need to explore novel treatment strategies. Solubilized sturgeon oil (SSO) has gained prominence for its anti-inflammatory effects in various contexts; however, its efficacy in UC has not yet been investigated. In this study, we investigated the preventive effects and underlying mechanisms of SSO in a dextran sulfate sodium-induced UC model. Oral administration of SSO significantly alleviated colitis severity by improving weight, disease activity index, and colon length. Moreover, SSO significantly downregulated the expression of interleukin (IL)-1β, IL-6, tumor necrosis factor-alpha, cyclooxygenase-2, and nitric oxide synthase, while enhancing the expression of tight junction-related proteins such as occludin and ZO-1 in colonic tissues. Additionally, SSO inhibited the activation of lipopolysaccharide-stimulated dendritic cells and macrophages and induced alterations in the gut microbiota, with increased and decreased abundances. Furthermore, colitis and gastrointestinal inflammation were alleviated in recipient mice that received fecal transplants from SSO-treated mice. These findings indicate that SSO is a promising natural therapeutic agent for preventing colitis by regulating the gastrointestinal microbiota and suppressing the hyperactivation of myeloid cells.
溃疡性结肠炎(UC)是一种炎症性肠病,可导致结肠黏膜发生炎症。UC的发病机制与胃肠道微生物群和免疫反应异常密切相关。目前UC的治疗主要是缓解症状,但存在一些缺点,尤其是长期使用时。因此,迫切需要探索新的治疗策略。可溶性鲟鱼油(SSO)因其在多种情况下的抗炎作用而受到关注;然而,其在UC中的疗效尚未得到研究。在本研究中,我们在葡聚糖硫酸钠诱导的UC模型中研究了SSO的预防作用及其潜在机制。口服SSO通过改善体重、疾病活动指数和结肠长度,显著减轻了结肠炎的严重程度。此外,SSO显著下调白细胞介素(IL)-1β、IL-6、肿瘤坏死因子-α、环氧化酶-2和一氧化氮合酶的表达,同时增强结肠组织中紧密连接相关蛋白如闭合蛋白和紧密连接蛋白-1的表达。此外,SSO抑制脂多糖刺激的树突状细胞和巨噬细胞的活化,并诱导肠道微生物群的改变,其丰度增加或减少。此外,接受来自SSO处理小鼠粪便移植的受体小鼠的结肠炎和胃肠道炎症得到缓解。这些发现表明,SSO是一种有前景的天然治疗剂,可通过调节胃肠道微生物群和抑制髓样细胞的过度活化来预防结肠炎。